Missed Nvidia in 2009? This Rare Signal Is Flashing Again.\u00a0In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia.\u00a0For the first time in years, that same “Total Conviction” signal is flashing for a company 1\/100th the size of Nvidia.\u00a0Continue \u00bb<\/a> <\/p>\n Mitapivat trial results <\/p>\n It’s here where it gets a bit complicated. In November, management released mixed results from the Phase 3 RISE UP trial of mitapivat in SCD. <\/p>\n The primary endpoint, hemoglobin response, and the key secondary endpoint, change from baseline in hemoglobin concentration, were met. <\/p>\n Mitapivat did “not meet statistical significance in the primary endpoint of annualized rate of SCPCs.” <\/p>\n The failure to meet the primary endpoint of SCPC reduction is an obvious concern, especially given that Novo Nordisk<\/a> later reported that its rival oral pyruvate kinase-R (PKR) activator improved hemoglobin response and demonstrated a statistically meaningful reduction in crisis events. <\/p>\n Fast forward to June, and Agios provided more detailed data from the RISE UP trial, noting that among patients in the mitapivat-treated group who reported a response in hemoglobin, there was a “clinically meaningful benefit across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes.” <\/p>\n An accelerated approval (decision due by Nov. 1) would be a major plus. Still, to gain full approval later, Agios has to demonstrate success in the confirmatory REIGNITE 3 trial, which the FDA requires as part of the accelerated approval process. <\/p>\n There’s still plenty for Agios to do, and competition is coming from a formidable rival, but Agios appears to have good chances of getting mitapivat approved for SCD this year. <\/p>\n Should you buy stock in Agios Pharmaceuticals right now? <\/p>\n Before you buy stock in Agios Pharmaceuticals, consider this: <\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Agios Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. <\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you’d have $407,651!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,252,823!* <\/p>\n Now, it’s worth noting\u00a0Stock Advisor’s total average return is 922% \u2014 a market-crushing outperformance compared to 208% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors. <\/p>\n See the 10 stocks \u00bb<\/a> <\/p>\n *Stock Advisor returns as of July 10, 2026. <\/p>\n Lee Samaha<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>. <\/p>\n<\/a> Image source: Getty Images. Where next for Agios Pharmaceuticals <\/p>\n